Universita Cattolica del Sacro Cuore, University Hospital Gemelli
Welcome,         Profile    Billing    Logout  
 3 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thuss-Patience, Peter
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
RAMIRIS, NCT03081143 / 2015-005171-24: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Active, not recruiting
2/3
429
Europe
FOLFIRI, Ramucirumab, Paclitaxel
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Gastric or EGJ Cancer
12/25
12/25
AIO-STO-0218, NCT03966118: Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

Recruiting
2
59
Europe
Avelumab, Ramucirumab, Paclitaxel
P. C. Thuss-Patience
Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma of the Stomach
09/22
09/23
Pozzo, Carmelo
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
RAMIRIS, NCT03081143 / 2015-005171-24: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Active, not recruiting
2/3
429
Europe
FOLFIRI, Ramucirumab, Paclitaxel
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Gastric or EGJ Cancer
12/25
12/25
IRMO, NCT06337019: The Italian Registry of Malnutrition in Oncology

Recruiting
N/A
1500
Europe
Cohort observational
Fondazione IRCCS Policlinico San Matteo di Pavia, Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Cancer, Cancer Metastatic
10/27
10/27

Download Options